victrelis boceprevir capsule
merck sharp & dohme corp. - boceprevir (unii: 89bt58kelh) (boceprevir - unii:89bt58kelh) - boceprevir 200 mg
victrelis
merck sharp & dohme (new zealand) limited - boceprevir 200mg - capsule - 200 mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 - victrelis (boceprevir) is indicated for the treatment of chronic hepatitis c (hcv) genotype 1 infection, in a combination regimen with peginterferon alpha and ribavirin, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.
victrelis
merck sharp dohme ltd - boceprevir - hepatitis c, chronic - antivirals for systemic use - victrelis is indicated for the treatment of chronic hepatitis-c (chc) genotype-1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
victrelis capsule
merck canada inc - boceprevir - capsule - 200mg - boceprevir 200mg - hcv antivirals
victrelis triple capsule
merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 80mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 80mcg - interferons
victrelis triple capsule
merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 100mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 100mcg - interferons
victrelis triple capsule
merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 120mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 120mcg - interferons
victrelis triple capsule
merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 150mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 150mcg - interferons
victrelis
merck sharp & dohme australia pty ltd - boceprevir -
victrelis® pegatron® combination therapy
merck sharp & dohme (new zealand) limited - boceprevir 200mg; peginterferon alfa-2b 100ug; ribavirin 200mg; - combination - 200mg/100mcg/200mg - active: boceprevir 200mg excipient: capsugel yellow 2276 capsugel yellow 4077 croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose pregelatinised maize starch sodium laurilsulfate tekprint red sb-1100 active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate dibasic sodium phosphate monohydrate polysorbate 80 sucrose active: ribavirin 200mg excipient: croscarmellose sodium gelatin lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate tekprint blue sb-6018 titanium dioxide water for injection - victrelis pegatron combination therapy is indicated for the treatment of chronic hepatitis c (chc) genotype 1 infection, in adult patients (18 years and older) with compensated liver disease who are previously untreated or who have failed previous therapy.